Abstract
Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
Current Diabetes Reviews
Title: Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Volume: 3 Issue: 3
Author(s): Scott D. Doughman, Srirama Krupanidhi and Carani B. Sanjeevi
Affiliation:
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
Abstract: Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Export Options
About this article
Cite this article as:
Scott D. Doughman , Srirama Krupanidhi and Carani B. Sanjeevi , Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA, Current Diabetes Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339907781368968
DOI https://dx.doi.org/10.2174/157339907781368968 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
Current Genomics Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) Autoimmune Hepatitis: Pathophysiology, Diagnosis and Pharmacological Therapy
Current Immunology Reviews (Discontinued) microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Protective Effects of Astragalus Membranaceus and Ligustrazine on Rat Brain Microvascular Endothelial Cell Injury after Oxygen-Glucose Deprivation/ Reoxygenation by Suppressing the PKCδ/MARCKS Pathway
Combinatorial Chemistry & High Throughput Screening Mechanisms of Beta-Blockers Action in Patients with Heart Failure
Reviews on Recent Clinical Trials Graphical Abstracts:
Current Cardiology Reviews Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Diagnosis of Drug-Induced Liver Disease
Current Clinical Pharmacology Embolic Protection Devices in Saphenous Vein Graft and Native Vessel Percutaneous Intervention: A Review
Current Cardiology Reviews Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Leptinaemia and Antiendothelial Antibodies in Accelerated Atherosclerosis – Is There a Relationship?
Vascular Disease Prevention (Discontinued) Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets